Literature DB >> 11519367

Voices from the field: providers discuss HIV counseling and testing programs for drug users.

M Downing1, N Mulia, K Vernon, K Knight, M Ferreboeuf, A Carroll.   

Abstract

The use of illicit drugs plays a critical role in the spread of HIV, with approximately one-half of all new HIV infections in the United States attributed to this mode of transmission. There is a renewed emphasis on developing special HIV counseling and testing (C&T) programs for drug users. We conducted a qualitative study of C&T providers to identify client-centered and structural barriers to providing HIV C&T to high-risk drug users. Interviews focused on obtaining a detailed description of the services; successful and problematic forms of organization, financing, and service delivery; client access and barriers to C&T services; recommendations for increasing C&T accessibility and utilization by drug users; and linkages between C&T and other HIV-prevention and intervention services. The results of our interviews illustrate that it is tremendously complex and challenging work to provide C&T to populations with multiple and immediate needs within a context of layered constraints on individual behavior, provider resources, and service delivery. Providers clearly understand client-centered and structural barriers and have demonstrated a commitment to overcoming the barriers related to AIDS stigma, confidentiality, material needs, and fear when delivering HIV C&T services.

Entities:  

Mesh:

Year:  2000        PMID: 11519367

Source DB:  PubMed          Journal:  AIDS Public Policy J        ISSN: 0887-3852


  2 in total

1.  Hepatitis C infection among drug users attending general practice.

Authors:  W Cullen; G Bury; J Barry; F D O'Kelly
Journal:  Ir J Med Sci       Date:  2003 Jul-Sep       Impact factor: 1.568

2.  A client-centered relational framework on barriers to the integration of HIV and substance use services: a systematic review.

Authors:  Rogério Meireles Pinto; Yun Chen; Sunggeun Ethan Park
Journal:  Harm Reduct J       Date:  2019-12-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.